Skip to main content
editorial
. 2020 Dec 2;33(3):e166–e171. doi: 10.1016/j.clon.2020.11.027

Fig 2.

Fig 2

Prevalence of highest reported Common Terminology Criteria for Adverse Events (CTCAE) toxicity for patients receiving a tumour bed boost versus no tumour bed boost (right and left column, respectively). No significant differences were found between groups.